# Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea

> **NCT01137136** · — · SUSPENDED · sponsor: **Samsung Medical Center** · enrollment: 300 (estimated)

## Conditions studied

- Polymorphism
- CYP19
- Aromatase Inhibitor

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01137136
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** SUSPENDED
- **Start date:** 2010-06
- **Primary completion:** 2014-12
- **Final completion:** 2015-12
- **Target enrollment:** 300 (ESTIMATED)
- **Why stopped:** Because of economic issue, we could just enrolled total 150 patients.
- **Last updated:** 2014-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01137136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01137136, "Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01137136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*